BRÈVE publiée le 08/05/2026 à 22:35, il y a 1 mois 18 jours Integrated BioPharma annonce une baisse de son chiffre d'affaires trimestriel Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Fabrication Sous Contrat
BRÈVE publiée le 08/05/2026 à 22:35, il y a 1 mois 18 jours Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
COMMUNIQUÉ DE PRESSE publié le 08/05/2026 à 22:30, il y a 1 mois 18 jours Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRÈVE publiée le 11/02/2026 à 22:35, il y a 4 mois 15 jours Integrated BioPharma annonce ses résultats financiers du quatrième trimestre 2025 Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Dépendance Du Client
BRÈVE publiée le 11/02/2026 à 22:35, il y a 4 mois 15 jours Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
COMMUNIQUÉ DE PRESSE publié le 11/02/2026 à 22:30, il y a 4 mois 15 jours Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRÈVE publiée le 10/11/2025 à 21:55, il y a 7 mois 16 jours Integrated BioPharma publie ses résultats financiers pour le troisième trimestre 2025 Résultats Financiers Baisse Des Revenus Résultat D'exploitation Revenu Net Fabrication Sous Contrat
BRÈVE publiée le 10/11/2025 à 21:55, il y a 7 mois 16 jours Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
COMMUNIQUÉ DE PRESSE publié le 10/11/2025 à 21:50, il y a 7 mois 16 jours Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRÈVE publiée le 23/09/2025 à 21:45, il y a 9 mois 3 jours Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
Publié le 26/06/2026 à 17:45, il y a 12 heures 45 minutes Descriptif du programme de rachat d'actions
Publié le 27/06/2026 à 01:40, il y a 4 heures 50 minutes Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Publié le 27/06/2026 à 00:00, il y a 6 heures 30 minutes Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 7 heures 30 minutes Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 7 heures 40 minutes Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 26/06/2026 à 22:15, il y a 8 heures 15 minutes Revive Therapeutics Announces Proposed Private Placement
Publié le 27/06/2026 à 00:05, il y a 6 heures 25 minutes EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 6 heures 26 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 54 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 54 minutes EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 7 heures 2 minutes EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
